SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 101 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $504,643 | -30.6% | 34,755 | 0.0% | 0.00% | -20.0% |
Q2 2023 | $727,422 | +8.9% | 34,755 | +9.9% | 0.01% | 0.0% |
Q1 2023 | $668,004 | -6.0% | 31,629 | +13.3% | 0.01% | -16.7% |
Q4 2022 | $710,742 | +9.4% | 27,927 | +3.3% | 0.01% | 0.0% |
Q3 2022 | $649,507 | +24.9% | 27,029 | 0.0% | 0.01% | +50.0% |
Q2 2022 | $520,038 | +10.7% | 27,029 | 0.0% | 0.00% | +33.3% |
Q1 2022 | $469,764 | +25.8% | 27,029 | +58.5% | 0.00% | 0.0% |
Q4 2021 | $373,290 | +14.5% | 17,053 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $325,883 | +11.3% | 17,053 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $292,800 | +16.8% | 17,053 | +52.1% | 0.00% | +50.0% |
Q1 2021 | $250,767 | +0.5% | 11,215 | 0.0% | 0.00% | -33.3% |
Q4 2020 | $249,422 | +50.7% | 11,215 | 0.0% | 0.00% | +50.0% |
Q3 2020 | $165,533 | -0.4% | 11,215 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $166,206 | +35.1% | 11,215 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $123,029 | – | 11,215 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |